Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of AS-Probionorm in Healthy Volunteers
NCT06252831Phase 1Completed
- Sponsor
- Industrial Microbiology
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AS-Probionorm in acute intestinal infection and dysbiosis, sponsored by Industrial Microbiology. Primary endpoints: Safety assessment criteria at 21 days and Tolerability of the study drug at 21 days. Started Sep 2023; status: completed.
02
Drugs
AS-Probionorm
03
Conditions
acute intestinal infectiondysbiosis
Beyond the preview
Go deeper on NCT06252831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252831.